

ations in the lung. Translation of our understanding of disease pathogenesis into clinical practice will bring us closer to our real goal – improving the lives of our patients and ultimately curing disease. With the publication of this study, IPF patients may someday breathe more easily.

Acknowledgments

The authors thank Jeffery Kutok for providing the mouse bone marrow sections used in Figure 2.

1. Gross, T.J., and Hunninghake, G.W. 2001. Idiopathic pulmonary fibrosis. *N. Engl. J. Med.* **345**:517–525.
2. King, T.E., Jr., et al. 2001. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. *Am. J.*

Respir. Crit. Care Med. **164**:1025–1032.

3. Kuhn, C., and McDonald, J.A. 1991. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. *Am. J. Pathol.* **138**:1257–1265.
4. Zhang, K., Rekhter, M.D., Gordon, D., and Phan, S.H. 1994. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. *Am. J. Pathol.* **145**:114–125.
5. Hashimoto, N., Jin, H., Liu, T., Chensue, S.W., and Phan, S.H. 2004. Bone marrow-derived progenitor cells in pulmonary fibrosis. *J. Clin. Invest.* **113**:243–252. doi:10.1172/JCI200418847.
6. Schrier, D.J., Kunkel, R.G., and Phan, S.H. 1983. The role of strain variation in murine bleomycin-induced pulmonary fibrosis. *Am. Rev. Respir. Dis.* **127**:63–66.
7. Prockop, D.J. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. *Science.* **276**:71–74.
8. Herzog, E.L., Chai, L., and Krause, D.S. 2003.

Plasticity of marrow-derived stem cells. *Blood.* **102**:3483–3493.

9. Bucala, R., Spiegel, L.A., Chesney, J., Hogan, M., and Cerami, A. 1994. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. *Mol. Med.* **1**:71–81.
10. Abe, R., Donnelly, S.C., Peng, T., Bucula, R., and Metz, C.N. 2001. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. *J. Immunol.* **166**:7556–7662.
11. Epperly, M.W., Guo, H., Gretton, J.E., and Greenberger, J.S. 2003. Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. *Am. J. Respir. Cell Mol. Biol.* **29**:213–224.
12. Kotton, D.N., et al. 2001. Bone marrow-derived cells as progenitors of lung alveolar epithelium. *Development.* **128**:5181–5188.
13. Ortiz, L.A., et al. 2003. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. *Proc. Natl. Acad. Sci. U. S. A.* **100**:8407–8411.
14. Iwano, M., et al. 2002. Evidence that fibroblasts derive from epithelium during tissue fibrosis. *J. Clin. Invest.* **110**:341–350. doi:10.1172/JCI200215518.

Bateman domains and adenosine derivatives form a binding contract

Bruce E. Kemp^{1,2}

¹St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia

²Commonwealth Scientific and Industrial Research Organisation (CSIRO) Health Sciences and Nutrition, Parkville, Victoria, Australia

Conserved pairs of CBS sequence motifs (named after cystathionine β -synthase) found in a wide variety of proteins associate to form Bateman domains. A new study establishes that Bateman domains bind adenosyl compounds and regulate IMP dehydrogenase, CBS, chloride channels, and AMP-activated protein kinase (see the related article beginning on page 274). This discovery reveals how mutations in CBS sequences in these proteins cause hereditary diseases and provides a rich vista of conceptual opportunities for therapies in energy metabolism, obesity, diabetes, cancer, antivirals, and immunosuppression.

J. Clin. Invest. **113**:182–184 (2004). doi:10.1172/JCI200420846.

What are CBS sequence motifs?

Alexander Bateman first recognized cystathionine β -synthase (CBS) sequences by looking for internal sequence duplications within proteins of the *Methanococcus janaschii* genome. These CBS se-

quences, typically 60 residues in length, occur as tandem pairs in a diversity of proteins, from archaeobacteria to eukaryotes (1, 2), including IMP dehydrogenase (IMPDH), whose protein crystal structure shows that CBS sequence pairs form a discrete structural domain (3) termed a Bateman domain (Figure 1) (4). Although it is known that mutations in CBS sequences alter the control functions of their parent proteins and cause hereditary diseases (5–7), the precise mechanisms involved were unknown. Mutations in CBS cause homocystinuria; IMPDH mutations cause retinitis pigmentosa; mutations in chloride channels (CLC1, CLC2, CLC5, and

CLCKB) cause a variety of conditions, including congenital myotonia, idiopathic generalized epilepsy, hypercalciuric nephrolithiasis, and classic Bartter syndrome; mutations in the AMP-activated protein kinase (AMPK) γ 2 subunit cause cardiac conductance problems similar to Wolff-Parkinson-White syndrome; and mutations in Hampshire pig γ 3 cause skeletal muscle glycogen storage disease.

Bateman domains bind adenosyl compounds

In this issue of the *JCI*, Scott and colleagues (8) have now found the missing link by showing that pairs of CBS sequences derived from AMPK, IMPDH-2, the chloride channel CLC2, and CBS bind adenosyl compounds (Figure 1). They show that AMPK, with its two pairs of CBS sequences, binds two molecules of AMP or ATP; the single pair of CBS sequences present in IMPDH allows it to bind a single mole of ATP, as does the pair of CBS sequences in CLC2. CBS binds a single mole of S-adenosyl methionine. The authors introduced known hereditary mutations into CBS sequences of the parent protein and found that they caused dramatic shifts in ligand-binding properties, which explained the loss of allosteric control of the parent protein. These findings will also influence research into the wider family of CBS-containing proteins (2) that includes other ion transporters, hemolysin, and poly(A) polymerase.

Address correspondence to: Bruce E. Kemp, St. Vincent's Institute of Medical Research, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia. Phone: 61-2-9288-2480; Fax: 61-3-9416-2676; E-mail: kemp@ariel.unimelb.edu.au.

Conflict of interest: The author has declared that no conflict of interest exists.

Nonstandard abbreviations used:

cystathionine β -synthase (CBS); IMP dehydrogenase (IMPDH); chloride channel (CLC); AMP-activated protein kinase (AMPK).




Figure 1

Pairs of CBS sequences within a protein fold into Bateman domains that bind adenosyl compounds and that mediate the allosteric control of their parent proteins. Shown is the surface-modeled Bateman domain formed by the CBS-1 and CBS-2 sequences of the AMPK γ subunit with AMP present in the central binding pocket (4). AdoMet, S-adenosyl methionine.

Regulation of IMPDH by ATP

IMPDH catalyzes the first committed step in the purine nucleoside-synthesis pathway for the generation of GMP. It converts IMP at the active site to xanthosine monophosphate, which is subsequently converted to GMP by GMP synthase. IMPDH activity is increased in proliferating cell types including cancers and activated peripheral blood lymphocytes. Because of this, IMPDH has been an important target for the design of anticancer and immunosuppressive drugs aimed at preventing cancer cell or lymphocyte proliferation. Drugs that inhibit IMPDH (e.g., ribavirin, mycophenolic acid, and VX-497) reduce cellular GTP and deoxy-GTP levels and can also have broad antiviral activities against both RNA viruses, such as respiratory syncytial virus, and DNA viruses, such as hepatitis B virus and human cytomegalovirus (9). Scott et al. (8) show that IMPDH is activated by ATP binding to its pair of CBS sequences (evidenced by a fourfold increase in V_{max}) and propose that this dependence on ATP acts as a checkpoint to ensure that guanine nucleotide synthesis only proceeds when sufficient ATP is available. Much of the IMPDH inhibitor design has focused on the NAD^+ cofactor- and IMP substrate-binding pockets within the active site. The findings of Scott et al. (8) now provide additional options for the design of IMPDH inhibitors that target the ATP-binding (allosteric activator) site; these options may offer

improved specificity for immunosuppressive, anticancer, and antiviral chemotherapy. IMP also serves as a precursor for AMP synthesis via adenylosuccinate. In this pathway, AMP inhibits conversion of IMP to adenylosuccinate. This begs the question of whether adenylosuccinate could also bind the IMPDH ATP-binding site and activate IMPDH. If so, this would provide a further tier of control between the GMP and AMP synthetic pathways.

Regulating energy metabolism via AMPK

The metabolic stress-sensing protein kinase AMPK has come to prominence recently for its role in the control of metabolism and gene transcription in response to exercise. It is responsible for regulating multiple metabolic pathways, including glucose transport, glycolysis, fatty acid, cholesterol, and triglyceride synthesis, as well as fatty acid oxidation. In addition, AMPK is activated by the adipocyte-derived hormones adiponectin and leptin together with two important drugs used to treat type 2 diabetes, metformin and rosiglitazone (10, 11). For these reasons there has recently been intense interest in AMPK as a target for the treatment of obesity, type 2 diabetes, and the metabolic syndrome.

AMPK consists of three subunits, a catalytic subunit α , an intracellular targeting subunit β , and a regulatory subunit γ . As mentioned above, the γ

subunits contain four copies of the CBS sequences. The γ subunits are encoded by three genes (γ 1, γ 2, and γ 3), and mutation in the γ 3 gene CBS sequence-1 causes the common Hampshire pig glycogen storage disease previously termed the *RN⁻* (Rendement Napole) mutation (12). Economically important alleles within the CBS-1 sequence of the γ 3 gene have now been found, which confer reduced muscle glycogen and enhanced meat quality (13). While no corresponding human γ 3 mutations have been reported, six families have been identified with mutations in AMPK γ 2 (expressed in the heart) that give rise to a cardiac phenotype with Wolff-Parkinson-White syndrome features (14). Scott et al. (8) have demonstrated that the γ subunit, with its two pairs of CBS sequences, binds two molecules of AMP and that the human mutations in these CBS sequences cause loss of AMP binding. Several earlier studies provided hints that the γ subunits were important for regulation by AMP but did not prove it. Hamilton et al. (15) introduced the equivalent γ 3 mutation found in Hampshire pigs into γ 1 and rendered the AMPK constitutively active, independent of AMP. Cheung et al. (16) showed that AMP could be chemically cross-linked to the γ subunit. While mutations in AMPK γ 2 cause a reduction in AMP binding, Scott et al. (8) found that they do not result in con-

stitutively active AMPK, so it is not yet clear how mutations in AMPK γ 2 cause the cardiac phenotype.

The crystal structure of IMPDH has allowed 3D modeling of the γ subunit CBS protein sequences by Scott et al. (8) and Adams et al. (4). A putative AMP-binding pocket comprising Arg-70, His-151, Arg-152, and Arg-171 has been identified in the γ 1 subunit CBS-1/CBS-1 sequence pairs (4). The presence of multiple basic residues in the binding site is also seen in the classical phosphorylase AMP site (17), the first example of an allosterically regulated enzyme, reported by Cori and Green 60 years ago (18). Of the important basic residues identified in the γ 1 subunit AMP-binding site, Arg-70 corresponds precisely to the site of one of the human γ 2 mutations, as well as the Hampshire pig γ 3 mutation and the original CBS mutation, D444N (5).

Knowledge of how AMPK binds AMP paves the way for rational drug design of AMPK activators and inhibitors

The binding of AMP to the γ subunit of AMPK influences the activation of AMPK in several ways. Activation of AMPK depends on phosphorylation by the tumor-suppressor protein kinase LKB1, which is mutated in most cancer patients with Peutz-Jeghers syndrome (19, 20). The binding of AMP makes AMPK a better substrate for LKB1, in addition to making it more resistant to inactivation by phosphatases. The likely link between AMPK and LKB1 in tumor suppression and cell-growth arrest adds yet another dimension to

the potential applications of therapeutic drugs based on the γ subunit AMP-binding site. With regard to health promotion, AMPK mediates a number of the benefits of exercise for metabolism and gene transcription, and this suggests that AMPK-activating drugs that target the γ subunit may increase exercise capacity.

The mark of an important discovery is that it changes our way of thinking. There are now well over a thousand known proteins that contain Bateman domains. For many of these proteins we can now begin to hypothesize about how they are regulated by adenosyl metabolites.

Acknowledgments

Bruce Kemp is supported by a Federation Fellowship from the Australian Research Council and by grants from the National Health and Medical Research Council and the National Heart Foundation, and sponsored by the Max Planck Research Award program.

1. The CBS domain web page. The Sanger Institute. <http://www.sanger.ac.uk/Users/agb/CBS/CBS.html>.
2. Bateman, A. 1997. The structure of a domain common to archaeobacteria and the homocystinuria disease protein. *Trends Biochem. Sci.* **22**:12–13.
3. Zhang, R., et al. 1999. Characteristics and crystal structure of bacterial inosine-5'-monophosphate dehydrogenase. *Biochemistry.* **38**:4691–4700.
4. Adams, J., et al. 2004. Intrasteric control of AMPK via the gamma-1 subunit AMP allosteric regulatory site. *Protein Sci.* In press.
5. Kluijtmans, L.A., et al. 1996. Defective cystathionine beta-synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient. *J. Clin. Invest.* **98**:285–289.
6. Pusch, M. 2002. Myotonia caused by mutations in the muscle chloride channel gene CLCN1. *Hum. Mutat.* **19**:423–434.
7. Bowne, S.J., et al. 2002. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. *Hum. Mol. Genet.* **11**:559–568.
8. Scott, J.W., et al. 2004. CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. *J. Clin. Invest.* **113**:274–284. doi:10.1172/JCI200419874.
9. Markland, W., McQuaid, T.J., Jain, J., and Kwong, A.D. 2000. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. *Antimicrob. Agents Chemother.* **44**:859–866.
10. Hardie, D.G. 2003. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. *Endocrinology.* **144**:5179–5183.
11. Kemp, B.E., et al. 2003. AMP-activated protein kinase, super metabolic regulator. *Biochem. Soc. Trans.* **31**:162–168.
12. Milan, D., et al. 2000. A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. *Science.* **288**:1248–1251.
13. Ciobanu, D., et al. 2001. Evidence for new alleles in the protein kinase adenosine monophosphate-activated gamma(3)-subunit gene associated with low glycogen content in pig skeletal muscle and improved meat quality. *Genetics.* **159**:1151–1162.
14. Gollob, M.H., Green, M.S., Tang, A.S., and Roberts, R. 2002. PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophy. *Curr. Opin. Cardiol.* **17**:229–234.
15. Hamilton, S.R., et al. 2001. An activating mutation in the gamma1 subunit of the AMP-activated protein kinase. *FEBS Lett.* **500**:163–168.
16. Cheung, P.C., Salt, I.P., Davies, S.P., Hardie, D.G., and Carling, D. 2000. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. *Biochem. J.* **346**:659–669.
17. Sprang, S.R., Withers, S.G., Goldsmith, E.J., Fletcher, R.J., and Madsen, N.B. 1991. Structural basis for the activation of glycogen phosphorylase b by adenosine monophosphate. *Science.* **254**:1367–1371.
18. Cori, G.T., and Green, A.A. 1943. Crystalline muscle phosphorylase II prosthetic group. *J. Biol. Chem.* **151**:31–38.
19. Hong, S.P., Leiper, F.C., Woods, A., Carling, D., and Carlson, M. 2003. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. *Proc. Natl. Acad. Sci. U. S. A.* **100**:8839–8843.
20. Hawley, S.A., et al. 2003. Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. *J. Biol.* **2**:28. PMID: 14511394.